Abstract
目的 探讨中药制剂糖眼明对糖尿病大鼠视网膜血管内皮细胞生长因子(VEGF)及细胞间黏附分子-1(ICAM-1)表达影响,从而了解其对糖尿病视网膜病变的防治机理.方法 制备糖尿病大鼠模型,分为正常组、糖眼明治疗组、糖尿病对照组及成模后3个月糖眼明治疗组.治疗3个月后糖眼明治疗组、糖尿病对照组及正常对照组取血测定血糖、血脂及糖化血红蛋白,取眼球制备视网膜病理切片,免疫组化染色观察10个高倍视野内糖尿病大鼠视网膜中ICAM-1及VEGF的阳性细胞计数.同时成模后3个月糖眼明治疗组开始给予糖眼明灌胃,其余3组原方案继续灌服3个月,6个月后所有大鼠取血测定血糖、血脂及糖化血红蛋白,取眼球制备视网膜病理切片、免疫组化染色,观察10个高倍视野内糖尿病大鼠视网膜中ICAM-1及VEGF的阳性细胞计数.结果 3个月时,糖尿病对照组及糖眼明组较正常对照组大鼠视网膜ICAM-1及VEGF的表达明显升高(P＜0.05);糖眼明组较糖尿病对照组明显减少(P＜0.05).6个月后,糖尿病对照组、糖眼明组及3个月糖眼明组较正常对照组大鼠视网膜ICAM-1及VEGF的表达进一步升高(P＜0.05);糖眼明组及3个月糖眼明组较糖尿病对照组明显减少(P＜0.05);且糖眼明组较3个月糖眼明组明显减少(P＜0.05);6个月后与3个月时比较,除正常组无明显变化外,糖尿病对照组及糖眼明组均较3个月时明显升高(P＜0.05).结论 糖眼明可以明显抑制糖尿病大鼠视网膜ICAM-1及VEGF的表达。
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
